Date | Price to Sales Ratio (P/S) | Price to Book Ratio (P/B) | Dividend Yield | Free Cash Flow Yield |
---|
CEO | Dr. Gaurav D. Shah M.D. |
IPO Date | Feb. 18, 2015 |
Location | United States |
Headquarters | 9 Cedarbrook Drive |
Employees | 268 |
Sector | Health Care |
Industries |
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. is headquartered in Cranbury, New Jersey.
Past 5 years
USD 39.01
USD 13.23
USD 15.00
USD 12.60
USD 1.51
USD 3.29
USD 39.83
USD 43.32
USD 11.24
USD 11.16
USD 78.14
USD 53.94
USD 8.68
USD 16.86
USD 5.77
USD 45.23
USD 10.49
USD 7.05
USD 1.72
USD 3.09
StockViz Staff
January 15, 2025
Any question? Send us an email